MYOK News and Press, MyoKardia Inc. From 03/27/19

MyoKardia ( MYOK -0.9% ) announced the pricing of an underwritten public offering of 4.93M shares of its common stock at a price of $51/share. More news on: MyoKardia, Inc., Read more ...

SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public...

SOUTH SAN FRANCISCO, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwrit...

MyoKardia ( MYOK ) is a slowly developing story with a two-year window of opportunity for investors before the company faces regulators. The company targets symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a disease where the heart muscle becomes abnormally thick, making it difficul...

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, wil...

MyoKardia (MYOK) Q4 2018 Results Earnings Conference Call March 04, 2019, 08:30 AM ET Company Participants Michelle Corral - Senior Director of Corporate Communications & IR Tassos Gianakakos - President, CEO William Fairey - Chief Commercial Officer & Executive VP Tayl...

MyoKardia ( MYOK +3.4% ) is up in early trade in response to positive results from an open-label extension study, PIONEER-OLE , evaluating mavacamten in 13 patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who completed the Phase 2 PIONEER-HCM study. The dat...

Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers Suggest Potential for Mavacamten to Slow or Reverse Disease Progression Conference Call...

MyoKardia (NASDAQ: MYOK ): Q4 GAAP EPS of -$0.39. More news on: MyoKardia, Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of serious cardiovascular diseases, today reported financial results for the fourth quarter an...